|
Hereditary gingival fibromatosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Aberrant activation of the hepatocyte growth factor (HGF) signaling axis has been associated with promoting various oncogenic programs during tumor initiation, progression, and treatment resistance.
|
29939324 |
2019 |
|
Hereditary gingival fibromatosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
ES was also found to down-regulate HGF-Met signaling in HGF-treated lung cancer cells.
|
31096000 |
2019 |
|
Hereditary gingival fibromatosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
<i>Results:</i> HSC-2 and HSC-3 cells expressed high EGFR levels, but hepatocyte growth factor (HGF) treatment induced cetuximab resistance, whereas the Met inhibitor PHA-665752 as well as Met siRNA was able to restore OSCC cell sensitivity to cetuximab.
|
31105843 |
2019 |
|
Hereditary gingival fibromatosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
To evaluate the safety, tolerability, and pharmacokinetics of recombinant 5-residue-deleted human hepatocyte growth factor (KP-100) injected intrathecally through an implantable catheter connected to a subcutaneous port, we conducted a first-in-human phase I trial of intrathecal KP-100 in 15 Japanese patients with amyotrophic lateral sclerosis.
|
30536581 |
2019 |
|
Hereditary gingival fibromatosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The role of aberrant hepatocyte growth factor receptor (c-MET, also known as tyrosine-protein kinase MET)/hepatocyte growth factor (HGF) signaling in cancer progression and invasion has been extensively studied. c-MET inhibitors have shown promising pre-clinical and early phase clinical trial anti-tumor activity in several tumor types, although results of most phase III trials with these agents have been negative.
|
30649748 |
2019 |
|
Hereditary gingival fibromatosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We also found dilatation index improved in HGF or VEGF165+HGF treated animals.
|
29787588 |
2018 |
|
Hereditary gingival fibromatosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we explored the role of hepatocyte growth factor (HGF) treatment on the endothelial-to-mesenchymal transition (EndMT) as a new way to target and prevent kidney fibrosis and improve outcomes for renal transplant recipients.
|
29292365 |
2018 |
|
Hereditary gingival fibromatosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Onartuzumab is an engineered single arm, monovalent monoclonal antibody that targets the MET receptor and prevents hepatocyte growth factor (HGF) signaling.
|
29893934 |
2018 |
|
Hereditary gingival fibromatosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Hepsin is a membrane-anchored serine protease whose role in hepatocyte growth factor (HGF) signaling and epithelial integrity makes it a target of therapeutic interest in carcinogenesis and metastasis.
|
29701962 |
2018 |
|
Hereditary gingival fibromatosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Decreased SOCS1 expression enhances regenerative response after biliary drainage (BD) resulting from AOC by upregulating hepatocyte growth factor (HGF) signaling.
|
28842621 |
2017 |
|
Hereditary gingival fibromatosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Moreover, intrathecal injection of naked plasmid encoding HGF gene (pUDK-HGF) significantly attenuated SNI-induced pain behaviors in mice by direct inhibition of spinal cord microglia and astrocyte activation.
|
29059509 |
2017 |
|
Hereditary gingival fibromatosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our previous work showed that hepatocyte growth factor (HGF) signaling elicits resistance to MEK inhibitors in metastatic uveal melanoma.
|
28138035 |
2017 |
|
Hereditary gingival fibromatosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
UNCL-Sema3E inhibited efficiently vascular endothelial growth factor-A (VEGF), platelet derived growth factor (PDGF) and basic fibroblast growth factor (bFGF) signaling in human umbilical vein derived endothelial cells (HUVEC) and to a lesser extent hepatocyte growth factor (HGF) signal transduction.
|
27725196 |
2016 |
|
Hereditary gingival fibromatosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The combined enhancement of neovascularization and fibrosis in paMSC-IGF-1/HGF-treated animals nonetheless suggests that sustained exposure to high IGF-1 + HGF levels promotes beneficial as well as deleterious effects that do not improve overall cardiac regeneration.
|
27423905 |
2016 |
|
Hereditary gingival fibromatosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Knockdown of c-Met inhibited the activation of the c-Met/PI3K/Akt pathway regardless of hepatocyte growth factor (HGF) treatment, and furthermore reduced the expression of miR-93 in these HCC cells. miR-93 also rendered cells to be more sensitive to sorafenib and tivantinib treatment.
|
25633810 |
2015 |
|
Hereditary gingival fibromatosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Hepatocyte growth factor (HGF) signaling promotes tumor invasiveness in renal cell carcinoma (RCC) and other cancers.
|
24914205 |
2014 |
|
Hereditary gingival fibromatosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Aberrant MET expression and hepatocyte growth factor (HGF) signaling are implicated in promoting resistance to targeted agents; however, the induced MET activation by epidermal growth factor receptor (EGFR) inhibitors mediating resistance to targeted therapy remains elusive.
|
24714091 |
2014 |
|
Hereditary gingival fibromatosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here we show that the fate of osteolytic bone metastasis depends on the balance among autophagy, anoikis resistance and ossification, and that the hepatocyte growth factor (HGF) signaling pathway seems to have an important role in orchestrating bone colonization.
|
24434513 |
2014 |
|
Hereditary gingival fibromatosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Heparanase plays a dual role in driving hepatocyte growth factor (HGF) signaling by enhancing HGF expression and activity.
|
21131364 |
2011 |
|
Hereditary gingival fibromatosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Hepatocyte growth factor (HGF) significantly blocked the cigarette smoke-induced apoptosis as shown by DNA profiling (10.8±1.5% of CSE+HGF, p<0.05), LIVE/DEAD staining (78.5±1.2% in CSE+HGF treated cells, p<0.05), and COMET assay (Apoptotic Index: 10.0±0.8% in CSE+HGF treated cells, P<0.05).
|
20850432 |
2010 |
|
Hereditary gingival fibromatosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Elevated levels of tissue inhibitor of metalloproteinases-1 (TIMP-1) render the liver more susceptible to metastasis by triggering urokinase plasminogen activator (uPA) expression as well as hepatocyte growth factor (HGF) signalling, thereby leading to the fatal scattered infiltration of metastasizing tumour cells throughout the parenchyma of the target organ.
|
19863693 |
2010 |
|
Hereditary gingival fibromatosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Kringle 1 domain of HGF (HGFK1) has been demonstrated as a potent anti-tumor molecule and p53 is a well established tumor suppressor.
|
18722051 |
2008 |
|
Hereditary gingival fibromatosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Here, we show that elevated stromal expression of TIMP-1 promotes liver metastasis in two independent tumor models by inducing the hepatocyte growth factor (HGF) signaling pathway and expression of several metastasis-associated genes, including HGF and HGF-activating proteases, in the liver.
|
17875701 |
2007 |
|
Hereditary gingival fibromatosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
One particularly promising candidate is the MET gene, which encodes a receptor tyrosine kinase that mediates hepatocyte growth factor (HGF) signaling in brain circuit formation, immune function, and gastrointestinal repair.
|
17696172 |
2007 |
|
Hereditary gingival fibromatosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
HGF and E-cadherin neutralizing antibody stimulated dispersion, and HGF significantly enhanced the invasion of hypopharyngeal cancer cells in a dose-dependent manner (P < .05).
|
17294073 |
2007 |